To study the efficacy of dapagliflozin (sodium glucose co transporter-2 inhibitor) in heart failure with reduced ejection fraction in tertiary care hospital in central india

Efficacy of Dapagliflozin in heart failure with reduced ejection fraction: An observational study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/079180

Enrollment

Registered

2025-01-21

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I509- Heart failure, unspecified

Interventions

Intervention1: Tab Dapagliflozin 10 MG OD for 12 months: Patient of heart failure with reduced ejection fraction who are enrolled for the study after obtaining informed consent will be observed for us

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of both genders aged 18 years or older. 2. Diagnosis of ischemic heart disease. 3. Fulfillment of the Framingham criteria for heart failure. 4. Left ventricular ejection fraction (LVEF) documented to be = 45% within the last 1-2 months. 5. Willingness to provide written informed consent. 6. Ability and willingness to adhere to SGLT-2 inhibitor therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Improvements in cardiometabolic parameters, NYHA class, and echocardiographic measures over the 12-month follow-up period. Furthermore, we expect to observe a reduction in cardiovascular death and recurrent hospitalization rates among patients receiving dapagliflozin therapy. Safety analyses will provide insights into the tolerability and adverse event profile of dapagliflozin in this patient population.Timepoint: The said outcome will be measured at baseline, 6 months and 12 months	—

Measure

Time frame

Improvements in cardiometabolic parameters, NYHA class, and echocardiographic measures over the 12-month follow-up period. Furthermore, we expect to observe a reduction in cardiovascular death and recurrent hospitalization rates among patients receiving dapagliflozin therapy. Safety analyses will provide insights into the tolerability and adverse event profile of dapagliflozin in this patient population.Timepoint: The said outcome will be measured at baseline, 6 months and 12 months

—

Secondary

Measure	Time frame
Improvements in KFT and LFT, Decrease in HBA1C levels, Signs of dehydration Timepoint: baseline, 6 months and 12 months	—

Countries

India

Contacts

Public ContactDr Meghna Bordoloi

Jawaharlal Nehru Medical College, Sawangi (meghe)

drshilpagaidhane@gmail.com9678861561

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026